Skip to main content

Common Medicines Tied to Urinary Incontinence


By David Douglas
NEW YORK (Reuters Health) Jun 11 - An apparent association between some common medications, including antihistamines and angiotensin II receptor blockers (ARBs), and urinary incontinence (UI) suggests a need for further study, researchers say.
Dr. Susan A. Hall of the New England Research Institutes, Watertown, Massachusetts, lead author of a report online May 15 in the Journal of Urology, told Reuters Health by email that her team found some associations that were not previously documented.
But, she added, the cross-sectional design of the research can't prove causality.
The population-based epidemiological study involved more than 5,500 men and women aged 30 to 79 years. Nine percent of women and 4.6% of men had urinary incontinence -- and these individuals were significantly older than those without such symptoms.
The prevalence of UI was then examined in users of 25 medication groups after adjustments for known urinary incontinence risk factors.
For women, the prevalence was highest among users of antihistamines (28.4%) and ARBs (22.9%). In men, the prevalence of UI was highest among users of ARBs (22.2%), followed by loop diuretics (19.1%).
UI odds ratios of more than 1.7 were established for women using certain antihistamines (OR 1.75), beta receptor agonists (OR 1.73), ARBs (OR 2.07), estrogens (OR 1.90) and anticonvulsants (OR 1.75).
Among men only anticonvulsants were associated with urinary incontinence after final adjustments (OR 2.5). ARBs showed an adjusted association of borderline significance.
"Future epidemiologic studies," Dr. Hall concluded, "should consider whether new use of these drugs is associated with incident incontinence."

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

FDA Decision Delayed for Truvada in HIV PrEP

June 11, 2012 — The US Food and Drug Administration (FDA) has delayed its decision on allowing the use of tenofovir disoproxil fumarate/emtricitabine ( Truvada , Gilead) as preexposure prophylaxis (PrEP) so that the proposed risk evaluation and mitigation strategy (REMS) can be reviewed. In early May, the FDA's Antiviral Drugs Advisory Committee  strongly backed  approval of the first-ever drug for the prevention of sexually acquired HIV-1 infection. However, concerns by the panel at the time included that people may neglect condom use if they feel they are protected by PrEP. Panelists were also concerned that uninfected people taking PrEP who become infected with HIV may not switch to a 3-drug regimen as recommended. According to the company, the FDA has postponed the target date to September 14 so it can review Gilead's REMS plan to help ensure that patients will not misuse the drug. The committee's recommendation for supplemental approval of tenofovir/emtricit...
Post a Comment
Read more

New and Generic Drug Approvals

September 5, 2012 Drug Name Active Ingredient Dosage Form/Route Sponsor Submission Type Amlodipine Besylate; Benazepril Hydrochloride amlodipine besylate; benazepril hydrochloride Capsule; Oral Aurobindo Pharma Ltd Approval Declomycin demeclocycline hydrochloride Tablet; Oral Corepharma Labeling Revision Trilipix choline fenofibrate Capsule, Delayed Release; Oral Abbott Labs Labeling Revision Trilipix choline fenofibrate Capsule, Delayed Release; Oral Abbott Labs Manufacturing Change or Addition Ziprasidone Hydrochloride ziprasidone hydrochloride Capsule; Oral Wockhardt Ltd Approval
1 comment
Read more